Abstract: Tuvusertib (M1774) is a potent, selective, and orally administered inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein kinase, currently under investigation for the treatment of advanced solid tumors. This review synthesizes available clinical and pharmacological data on tuvusertib, focusing on its application as both a monotherapy and in solid tumor combination therapies. Clinical evaluations demonstrate that tuvusertib has a manageable safety profile, with anemia identified as the primary dose-limiting toxicity. The drug exhibits dose-proportional pharmacokinetics and achieves significant target engagement, measured by ɤ-H2AX inhibition. Furthermore, population pharmacokinetic and pharmacodynamic modeling indicates a lack of ethnic sensitivity, supporting its inclusion in simultaneous global multiregional clinical trials (MRCTs). Ongoing research is expanding its clinical utility by exploring combination regimens, such as with the immunotherapy avelumab, to enhance efficacy in specific solid tumors like Merkel cell carcinoma.
1. Introduction
The development of targeted therapies has significantly advanced the treatment landscape for solid tumors. Tuvusertib (also known as M1774) is a novel, orally administered, potent, and selective inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein kinase [1]. ATR is a critical component of the DNA damage response (DDR) pathway, making it an attractive therapeutic target in oncology. Tuvusertib is currently being evaluated in phase I and II clinical trials both as a monotherapy and in combination settings for patients with advanced solid tumors [1]. A notable direction in its clinical development is solid tumor combination therapy, exemplified by the MATRiX trial, which is testing the safety and effectiveness of tuvusertib in combination with the anti-PD-L1 antibody avelumab for the treatment of Merkel cell skin cancer [1].
2. Pharmacological Activity
The pharmacological profile of tuvusertib was extensively characterized in part A1 (monotherapy dose escalation) of an open-label, first-in-human (FIH) phase I trial (NCT04170153) involving 55 patients with advanced solid tumors [1]. Tuvusertib was administered at doses ranging from 5 to 270 mg once daily (q.d.). The drug was rapidly absorbed and demonstrated dose-proportional pharmacokinetics (PK) up to 180 mg. It exhibited a mean half-life (t1/2) ranging from approximately 1.2 to 5.6 hours, with minimal accumulation following once-daily administration [1].
The maximum tolerated dose (MTD) under continuous dosing was established at 180 mg q.d. To optimize the safety profile, a schedule of 180 mg q.d. administered in a 2-week on/1-week off cycle was declared the recommended dose for monotherapy expansion [1]. Furthermore, clinical PK data and population pharmacokinetic/pharmacodynamic (PK/PD) modeling demonstrated consistent exposure and safety profiles between Asian and non-Asian populations, indicating a low risk of ethnic sensitivity and enabling Asia-inclusive global clinical development [1].
3. Molecular Mechanism of Action
Tuvusertib functions as a selective inhibitor of the ATR protein kinase, an essential enzyme involved in sensing and repairing DNA replication stress and DNA damage [1]. By inhibiting ATR, tuvusertib disrupts the DNA damage response, leading to the accumulation of unresolved DNA damage and subsequent tumor cell death. In clinical settings, the molecular target engagement of tuvusertib is quantified by measuring the inhibition of ɤ-H2AX in the blood. Exposure-related target engagement, defined as greater than 80% inhibition of ɤ-H2AX, was successfully attained in patients at doses of 130 mg and above [1].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical structure or a comprehensive structure-activity relationship (SAR) for tuvusertib, it highlights key metabolic characteristics related to its molecular design. Tuvusertib is primarily metabolized by the enzyme aldehyde oxidase (AO) [1]. In vitro and clinical PK data indicate that there are no relevant ethnic differences in AO function, which contributes to the consistent pharmacokinetic behavior of the compound across diverse patient populations [1].
5. Current Limitations
The primary clinical limitation of tuvusertib observed during the dose-escalation phase is hematological toxicity. The most frequently reported dose-limiting toxicity (DLT) was anemia, which was found to be both dose- and exposure-related [1]. A longitudinal semi-mechanistic, multivariate population PK/PD model was required to predict the time course of reticulocytes, red blood cells, and hemoglobin (Hb) reduction [1]. Because of this exposure-related anemia, continuous daily dosing at the MTD is limited, necessitating an intermittent dosing schedule (2-week on/1-week off) to maintain a favorable safety profile [1].
6. Future Perspectives
The future development of tuvusertib is heavily focused on its integration into solid tumor combination therapies. By leveraging its mechanism of action in the DNA damage response pathway, tuvusertib is poised to synergize with other therapeutic modalities, such as immune checkpoint inhibitors (e.g., avelumab in the MATRiX trial for Merkel cell carcinoma) [1]. Additionally, the robust quantitative clinical pharmacology and Totality of Evidence approach that demonstrated low ethnic sensitivity for tuvusertib has paved the way for seamless, Asia-inclusive multiregional clinical trials (MRCTs). This strategy allows for the simultaneous global development of tuvusertib, ensuring that diverse patient populations, including those in China and Japan, can participate in early-phase dose confirmation cohorts and subsequent pivotal trials without the need for delayed, region-specific bridging studies [1].
